10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CYBA Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP12149b

Specification

CYBA Antibody (C-term) Blocking peptide - Product Information

Primary Accession P13498

CYBA Antibody (C-term) Blocking peptide - Additional Information

Gene ID 1535

Other Names
Cytochrome b-245 light chain, Cytochrome b(558) alpha chain, Cytochrome b558 subunit alpha, Neutrophil cytochrome b 22 kDa polypeptide, Superoxide-generating NADPH oxidase light chain subunit, p22 phagocyte B-cytochrome, p22-phox, p22phox, CYBA

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CYBA Antibody (C-term) Blocking peptide - Protein Information

Name CYBA (HGNC:2577)

Function
Critical component of the membrane-bound oxidase of phagocytes that generates superoxide. Associates with NOX3 to form a functional NADPH oxidase constitutively generating superoxide.

Cellular Location
Cell membrane. Note=As unassembled monomer may localize to the endoplasmic reticulum {ECO:0000250|UniProtKB:Q61462}

CYBA Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

CYBA Antibody (C-term) Blocking peptide - Images

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CYBA Antibody (C-term) Blocking peptide - Background

Cytochrome b is comprised of a light chain (alpha) and aheavy chain (beta). This gene encodes the light, alpha subunitwhich has been proposed as a primary component of the microbicidaloxidase system of phagocytes. Mutations in this gene are associatedwith autosomal recessive chronic granulomatous disease (CGD), thatis characterized by the failure of activated phagocytes to generatesuperoxide, which is important for the microbicidal activity ofthese cells.

CYBA Antibody (C-term) Blocking peptide - References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010)Katakami, N., et al. Atherosclerosis 212(2):534-538(2010)Tu, Y.C., et al. Acta Pharmacol. Sin. 31(7):874-880(2010)Moreno, M.U., et al. Drug News Perspect. 23(5):316-324(2010)Cross, D.S., et al. BMC Genet. 11, 51 (2010) :